Application of AXL expression as a marker of poor prognosis and a crucial mediator of cell invasion was proposed for early-stage CRC, specifically in the adjuvant disease in the cases of unsuccessful EGFR/VEGF–targeted therapies (42). Here, AXL is linked to colorectal carcinoma.